<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>23 Chronic lymphocytic leukaemia</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-22-acute-leukaemia.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 57.5%;"></div>
                        </div>
                       <span class="progress-text">Lecture 23 of 40</span>
                    </div>
                    <a href="haematology-24-myeloma.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">23 Chronic lymphocytic leukaemia</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                
                <section id="cll-intro" class="content-section" aria-labelledby="section-heading-1">
                    <div class="content-card">
                        <p>Chronic lymphocytic leukaemia (CLL) is a B-cell clonal lymphoproliferative disease in which lymphocytes accumulate in the blood, bone marrow and often in the lymph nodes and spleen (absolute lymphocyte count &gt;5.0 x 10<sup>9</sup>/L). A disease of older patients (peak age 72), it is the commonest leukaemia in Western countries (over 70 new cases/million population/year in the UK, male/female ratio 2:1) but is rare in Asia.</p>
                    </div>
                </section>

                <section id="aetiology-pathophysiology" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                        <span class="heading-text">Aetiology and pathophysiology</span>
                    </h2>
                    <div class="content-card">
                        <p>The cause is unknown. Commonest chromosome changes are trisomy 12, a 13q deletion and deletions of 11q including the ataxia telangiectasia gene. Oncogene mutations or deletions occur which may prevent cells from undergoing programmed cell death (apoptosis).</p>
                    </div>
                </section>

                <section id="clinical-features" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                        <span class="heading-text">Clinical features</span>
                    </h2>
                    <div class="content-card">
                        <p>Stages depend on clinical and laboratory findings (Fig. 23.1).</p>
                        <ul>
                            <li>Many cases (Stage A) are symptomless and diagnosed on routine blood test.</li>
                            <li>Presenting features include lymphadenopathy (typically symmetrical, painless and discrete), night sweats, loss of weight, symptoms of bone marrow failure.</li>
                            <li>Spleen is often moderately enlarged.</li>
                            <li>Hypogammaglobulinaemia and reduced cell-mediated immunity predispose to bacterial and viral infection.</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-063-1.jpg" alt="Fig. 23.1 Diagram illustrating the clinical course and staging of chronic lymphocytic leukaemia (CLL) using the Binet system, showing progression from asymptomatic Stage A to more advanced stages requiring treatment." class="content-image">
                            <figcaption>Fig. 23.1 The clinical course of chronic lymphocytic leukaemia (CLL). The Binet staging system evaluates enlargement of the following: lymph nodes, whether unilateral or bilateral, in the head and neck, axillae and inguinal regions; spleen and liver. Stage A patients are usually asymptomatic and do not require treatment. The peripheral blood lymphocyte count may rise progressively. Stage B patients often require treatment (e.g. with oral chlorambucil). Stage C patients will often respond to more intensive therapy (fludarabine, combination chemotherapy (CCT)).</figcaption>
                        </figure>
                    </div>
                </section>

                <section id="laboratory-findings" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                        <span class="heading-text">Laboratory findings</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Increased peripheral blood lymphocytes (Fig. 23.2 usually 10-30 x 10<sup>9</sup>/L at presentation) which are B cells (CD19, CD22 and also CD5 positive).</li>
                            <li>They have weak expression of surface IgM which is monoclonal (expressing only $\kappa$ or only $\lambda$ light chains).</li>
                            <li>Serum immunoglobulins are depressed.</li>
                            <li>Anaemia and thrombocytopenia may occur due to marrow infiltration or as a result of auto-antibodies.</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-064-1.jpg" alt="Fig. 23.2 Peripheral blood film in chronic lymphocytic leukaemia, showing a high number of mature lymphoid cells and some 'smear' cells." class="content-image">
                            <figcaption>Fig. 23.2 Chronic lymphocytic leukaemia: peripheral blood film showing large numbers of mature lymphoid cells and some 'smear' cells.</figcaption>
                        </figure>
                    </div>
                </section>

                <section id="course-prognosis" class="content-section" aria-labelledby="section-heading-5">
                    <h2 id="section-heading-5" class="section-heading">
                        <span class="heading-text">Course and prognosis</span>
                    </h2>
                    <div class="content-card">
                        <p>Patients may present at an early stage and subsequently remain stationary, progress or may present with late-stage disease. Some patients need no treatment for 10 years or more whilst in others the disease follows an aggressive course. Immunoblastic transformation (Richter's syndrome) may be a terminal event.</p>
                    </div>
                </section>

                <section id="treatment" class="content-section" aria-labelledby="section-heading-6">
                    <h2 id="section-heading-6" class="section-heading">
                        <span class="heading-text">Treatment</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Observation only for asymptomatic Stage A patients.</li>
                            <li>Oral chlorambucil to lower the lymphocyte count and reduce lymph node and spleen size.</li>
                            <li>Corticosteroids for bone marrow failure due to infiltration and for autoimmune haemolytic anaemia or thrombocytopenia.</li>
                            <li>The purine analogue fludarabine is valuable, either alone or in combination.</li>
                            <li>Combination chemotherapy e.g. CHOP (see Chapter 26).</li>
                            <li>Support care (Chapter 39).</li>
                            <li>Splenectomy or splenic irradiation is useful if the spleen is large and causes symptoms as a result of hypersplenism.</li>
                        </ul>
                    </div>
                </section>

                <section id="variants" class="content-section" aria-labelledby="section-heading-7">
                    <h2 id="section-heading-7" class="section-heading">
                        <span class="heading-text">Variants of chronic Iymphocytic Ieukaemia</span>
                    </h2>
                    <div class="content-card">
                        <p>Prolymphocytic leukaemia (PLL, Fig. 23.3a) resembles CLL but usually occurs in older (&gt;70 years) patients, the white cell count is high and responds poorly to treatment.</p>
                        <p>Hairy cell leukaemia (HCL, Fig. 23.3b) is rare (male/female ratio of 4:1, peak age of 55 years), presents with splenomegaly and pancytopenia. 'Hairy cells' are present in bone marrow and blood. Infections are frequent. They are B cells which stain for tartrate resistant acid phosphatase. Effective treatments include 2-chlorodeoxyadenosine (2-CDA) deoxycoformycin, interferon-$\alpha$ and splenectomy.</p>
                        <p>T-cell variants of CLL, PLL and HCL are much rarer than B-cell type and are more aggressive.</p>
                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-064-2.jpg" alt="Fig. 23.3 Two blood films: (a) Prolymphocytic leukaemia, and (b) Hairy cell leukaemia, showing the characteristic cell morphologies for each condition." class="content-image">
                            <figcaption>Fig. 23.3 (a) Prolymphocytic leukaemia: blood film. (b) Hairy cell leukaemia: blood film.</figcaption>
                        </figure>
                    </div>
                </section>

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-22-acute-leukaemia.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 57.5%;"></div>
                        </div>
                       <span class="progress-text">Lecture 23 of 40</span>
                    </div>
                    <a href="haematology-24-myeloma.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>